FRANKFURT (Reuters) - Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.
* Shares up 4 percent, outperforming sector index (Adds CEO comment, detail on pharma business)
(Adds Merck , Auxilium Pharmaceuticals, Aberdeen, Clorox and Northern Tier Energy; updates Seamless)
NEW YORK, Sept 22 (Reuters) - Sigma-Aldrich shares were surging on Monday, up 34.4 percent to $137.60 after German drugs and chemicals maker Merck KGaA said on Monday it agreed to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.
Merck 's internal research and development has ..... a major threat from generic competition. Merck 's restructured and more focused R&D programs ..... should yield increased productivity. We give Merck KGaA a Standard Stewardship Rating. Since
potentially mask any domestic progress. We're raising our fair value estimate for Sigma to $140 per share to reflect Merck KGaA's takeover offer announced in September. On a stand-alone basis, we place Sigma's fair value at $87 per share
Drugs and chemicals producer Merck KGaA agrees to acquire St. Louis-based Sigma-Aldrich (NASDAQ: SIAL ) for $140 per share in cash. The $17B deal represents
FRANKFURT, Sept 22 (Reuters) - German drugs and chemicals maker Merck KGaA said on Monday it agreed to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.
Merck KGaA intends to expand the company’s life ..... share. The deal will continue to diversify Merck ’s operations, while also enhancing the company ..... value estimate and economic moat rating for Merck . At nearly 20 times EBITDA, we think the deal